Welcome to our dedicated page for Sorrento Therapeutics news (Ticker: SRNEQ), a resource for investors and traders seeking the latest updates and insights on Sorrento Therapeutics stock.
Sorrento Therapeutics, Inc. (SRNEQ) is a clinical-stage biopharmaceutical leader developing innovative therapies for cancer, autoimmune disorders, and critical inflammatory conditions. This dedicated news hub provides investors and industry professionals with timely updates on the company's progress in bringing transformative treatments to market.
Access a centralized repository of official announcements including clinical trial milestones, regulatory developments, and strategic partnerships. Track updates across Sorrento's diverse pipeline spanning next-generation antibody therapies, car-t treatments for solid tumors, and non-opioid pain management solutions.
Our curated news collection serves as an essential resource for monitoring Sorrento's advancements in biosimilar development, oncolytic virus research, and diagnostic innovations. Bookmark this page to stay informed about the company's latest scientific breakthroughs and corporate developments directly from primary sources.
Sorrento Therapeutics, Inc. (OTC: SRNEQ) announced on April 25, 2023, that the U.S. Bankruptcy Court for the Southern District of Texas extended the restrictions on the transfer of shares for Scilex Holding Company, distributed as a dividend on January 19, 2023. This extension defers the selling, transferring, or disposing of these distributed shares from May 11, 2023, to September 1, 2023. The restrictions apply solely to the Distributed Stock and do not affect other Scilex securities held by Sorrento. Sorrento is focused on developing therapies for cancer, pain, and infectious diseases and has ongoing clinical trials for several novel products.
FAQ
What is the market cap of Sorrento Therapeutics (SRNEQ)?
